About

PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, can significantly reduce side effects caused by antibody drugs, making antibody therapy safe and effective. [Features of Core Technology (Antibody Lock)] ‧Higher masking ability and removal ability ‧Low immunogenicity ‧Prevention of anti-drug antibody binding ‧Prolonged serum half-life [Lead Product] PSM101, the lead candidate for head and neck cancer and colorectal cancer treatment, will complete stable cell clone generation in 2023 and the non-human primate side effect test in 2024-Q1. [Partnering] Through the (1) co-development of Lock-antibodies and (2) customized Antibody Lock design service, PrecisemAb licenses out Lock-antibodies to global pharma for conducting further clinical trials. About PrecisemAb Biotech Co., Ltd. PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, allows antibody drugs, including ADC and bispecific antibodies, to take effect only in diseased areas, solving systemic toxicity and making antibody treatment safe and effective. Now, we are developing the first-in-class antibody drug, PSM101, for advanced head and neck cancer. [Features of Antibody Lock] ★Medication safety with minimized adverse effects ★Elevating treatment efficacy for cancer cure ★Precision-designed for targeting various cancers [Partnering] PrecisemAb licenses Lock-antibodies for further clinical trials through: (1) Co-development of Lock-antibodies: [Oncology] Lock-EGFR, Lock-PD1, Lock-CTLA4, Lock-4-1BB [Autoimmune disease] Lock-TNFα, Lock-IL-1β (2) Customized Antibody Lock Design Service: Including 4 steps to design your own Lock-antibody. About PrecisemAb Biotech Co., Ltd. PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, allows antibody drugs, including ADC and bispecific antibodies, to take effect only in diseased areas, solving systemic toxicity and making antibody treatment safe and effective. Now, we are developing the first-in-class antibody drug, PSM101, for advanced head and neck cancer. [Features of Antibody Lock] ★Medication safety with minimized adverse effects ★Elevating treatment efficacy for cancer cure ★Precision-designed for targeting various cancers [Partnering] PrecisemAb licenses Lock-antibodies for further clinical trials through: (1) Co-development of Lock-antibodies: [Oncology] Lock-EGFR, Lock-PD1, Lock-CTLA4, Lock-4-1BB [Autoimmune disease] Lock-TNFα, Lock-IL-1β (2) Customized Antibody Lock Design Service: Including 4 steps to design your own Lock-antibody. Company Overview Founded in October 2021, PrecisemAb Biotech was established by the late Professor Tian-Lu Cheng, former Vice President of Kaohsiung Medical University (KMU), as a KMU spin-off company. PrecisemAb focuses on applying the exclusively licensed Universal Antibody Lock Technology to develop next-generation precision antibody drugs with high specificity, low side effects, and enhanced therapeutic efficacy. Innovations & Advantages of the Universal Antibody Lock Platform The Universal Antibody Lock Technology integrates a Hinge + Linker structure that connects the VL/VH domains of an antibody. This unique design prevents antibodies from binding to healthy tissues until they reach the tumor microenvironment (TME). The Hinge-based lock, derived from human IgG1, serves as a masking mechanism, reducing unwanted interactions with normal tissues. The Linker, optimized through computational modeling, includes tumor-specific protease cleavage sites and spatial adjustment regions that ensure precise activation in the tumor microenvironment (TME). This mechanism enables antibodies to remain inactive in normal tissues and only activate when exposed to tumor-specific proteases, thereby minimizing off-target toxicity and enhancing therapeutic efficacy. By selectively triggering antibody activation at the tumor site, this technology significantly reduces side effects and improves treatment outcomes, ultimately enhancing patient quality of life. Compared to competing platforms, the Universal Antibody Lock Technology offers several key advantages. First, the human IgG1 hinge-based lock has low immunogenicity, reducing the risk of anti-drug antibody (ADA) formation and avoiding interference with drug efficacy. Second, the platform is highly versatile, allowing seamless integration into monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and bispecific antibodies (BsAbs), which accelerates the development timeline for Lock-antibody drugs. Third, the linker design, incorporating tumor-specific protease cleavage sites and spatial adjustment regions, delivers the highest antibody activation rate globally in TME. The Universal Antibody Lock Technology has been adopted for industry collaboration. In May 2024, GlycoNex Biotech signed a non-exclusive licensing agreement with PrecisemAb, further demonstrating its applicability in antibody drug development. Drug Development (1) PrecisemAb's lead drug, PSM101 (Lock-EGFR antibody), is designed for EGFR-expressing cancers, including head and neck cancer and colorectal cancer. The drug has successfully completed in vitro and in vivo efficacy and safety studies, cell line development, upstream process optimization (yield: 4.2 g/L), downstream process optimization, formulation research, and accelerated stability testing. PSM101 is planned for IND submission to the US FDA and TFDA in Q4 2026. (2) Additionally, PSM915 (Lock-TNF-α) has been evaluated in Biomedcode’s rheumatoid arthritis (RA) mouse model, demonstrating its ability to suppress RA disease progression and improve drug safety.